HOME >> MEDICINE >> NEWS
Randomized trial of two therapies for acute lymphocytic leukemia finds survival advantage

Orlando, May 16, 2005 -- A prospective, randomized trial comparing a novel regimen with a standard treatment for adult patients with acute lymphocytic leukemia (ALL) showed a distinct advantage that continued to show superior results at three-, four-, and five-year intervals in the investigational arm of the trial. The drugs were given as induction therapy, an initial chemotherapy treatment with the goal of putting a patient's leukemia into complete remission. Patients who received the investigational regimen, comprised of cytarabine with high-dose mitoxantrone, also experienced a higher frequency of complete remission compared with patients on a standard, vincristine plus prednisone-based regimen. Mark A. Weiss, MD, a leukemia specialist at Memorial Sloan-Kettering Cancer Center and lead author of the eight-year, multicenter study, presented the study results today at the annual meeting of the American Society for Clinical Oncology.

"There have been very few randomized trials in adult ALL. This is probably the first study in 20 years that focuses on induction therapy, and it appears to show that one treatment is superior to another in putting the disease in remission," explained Dr. Weiss. "Although the survival rates for these patients were initially similar in both arms, the results diverged after two years. Patients treated with cytarabine plus high-dose mitoxantrone appeared to have a survival advantage at three, four, and five years. The difference in survival rates seemed even more pronounced for the subset of ALL patients with the Philadelphia chromosome, a genetic predisposition that makes the disease more difficult to treat," he said.

The trial looked at two regimens to be used as induction therapy. One hundred and sixty-four patients with ALL, who were able to participate in the trial, were randomized to receive either a standard regimen (L-20) of vincristine, prednisone, cyclophosphamide, and doxorubicin or the ALL-2 regimen of cytara
'"/>

Contact: Joanne Nicholas
nicholaj@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
16-May-2005


Page: 1 2 3

Related medicine news :

1. Randomized study indicates that patients with herniated disk improved with or without surgery
2. Randomized trial in Zimbabwe suggests how to make HIV testing and counselling attractive
3. New contracts support clinical trials on antibiotic-resistant, community-acquired staph infections
4. Warfarin better than aspirin at stroke prevention in elderly people with atrial fibrillation
5. Helicopter flight trials for EGNOS
6. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
7. GSK announces launch of largest ever Phase III trial in lung cancer treatment
8. Bias in statin trials, failure to control malaria, and more
9. International journal group updates guidelines on registration of clinical trials
10. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
11. Childrens Hospital and Pitt lead national trial of hypothermia to treat pediatric brain injury

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/24/2017)... (PRWEB) , ... September 24, 2017 , ... “The Messiah ... comparisons from biblical texts to firsthand experiences. “The Messiah 8 with the 3rd Anti ... matter how hard I’ve tried to look at all the angles of life,” Velazquez ...
(Date:9/24/2017)... , ... September 24, 2017 , ... “Star of Bethlehem ... of Bethlehem Study” is the creation of published author, Duane Engdahl, an investigator who ... by Christian Faith Publishing, Duane Engdahl’s new book is a thought-provoking essay an event ...
(Date:9/23/2017)... ... September 23, 2017 , ... A September ... obesity of Robert Kushner, director of Chicago’s Center for Lifestyle Medicine at Northwestern ... habits, the article notes that the center routinely recommends weight loss surgeries for ...
(Date:9/23/2017)... ... ... “You Can't Win Them All”: the story of an entrepreneur and a family ... changed the lives of young athletes. “You Can't Win Them All” is the ... Schreiber, a small town in Northern Ontario, Canada. He is an entrepreneur who ...
(Date:9/22/2017)... ... September 22, 2017 , ... On Sunday, September 24, ... 5K honoring Olympian, Florence Joyner, still considered the fastest woman of all time. ... Jo’s daughter, Mary Joyner, will sing the National Anthem. Mary was a contestant ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical ... independent supplier of medical equipment, supplies, drugs, vaccines, and ... has entered into an agreement to acquire Vantage Medical ... based in Holtsville, New York . ... in supplying new and emerging medical practices, will operate ...
Breaking Medicine Technology:
Cached News: